AVROBIO Announces Updated Clinical Data for AVR-RD-01 Gene Therapy in Fabry Disease
October 01, 2018 07:00 ET
|
AVROBIO, Inc.
First two patients in Phase 1 study continue to demonstrate AGA enzyme activity above the diagnostic range for classic Fabry disease 18 months and six months after receiving AVR-RD-01, respectively;...
AVROBIO, Inc. to Present at Upcoming Investor Conferences
August 28, 2018 08:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
August 09, 2018 08:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. to Present at the 2018 Wedbush PacGrow Healthcare Conference
August 08, 2018 08:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative...
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors
June 27, 2018 08:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical stage gene therapy company focused on developing potentially curative lentiviral-based gene...
AVROBIO, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Overallotment Option
June 25, 2018 16:30 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo...
AVROBIO, Inc. Announces Pricing of Initial Public Offering
June 20, 2018 20:42 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (the “Company”), a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based...